Mirae Asset Global Investments Co., Ltd. Mirati Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$132.01 - $190.29 $1.03 Million - $1.49 Million	-7,818 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $91,433 - $122,795	692 Added 9.71%	7,818 $1.38 Million
Q2 2021 Aug 11, 2021	BUY	$144.0 - $179.73 $117,504 - $146,659	816 Added 12.93%	7,126 $1.15 Million
Q1 2021 May 13, 2021	BUY	$158.92 - $221.61 $72,944 - $101,718	459 Added 7.84%	6,310 $1.08 Million
Q4 2020 Feb 10, 2021	BUY	$162.05 - $240.27 $263,169 - $390,198	1,624 Added 38.42%	5,851 $1.29 Million
Q3 2020 Nov 12, 2020	SELL	$113.26 - $167.27 $262,989 - $388,400	-2,322 Reduced 35.46%	4,227 $702,000
Q2 2020 Aug 11, 2020	BUY	$72.01 - $120.39 $60,416 - $101,007	839 Added 14.69%	6,549 $748,000
Q1 2020 May 12, 2020	BUY	$69.78 - $116.21 $84,503 - $140,730	1,211 Added 26.92%	5,710 $439,000
Q4 2019 Feb 12, 2020	BUY	$70.76 - $128.86 $11,533 - $21,004	163 Added 3.76%	4,499 $580,000
Q3 2019 Nov 12, 2019	BUY	$77.91 - $109.6 $337,817 - $475,225	4,336 New	4,336 $338,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.